Orion Oyj

Legal Proceedings Report • Jun 10, 2022

Disclosure 409844

Orion - Other information disclosed according to the rules of the Exchange

Charges pressed by prosecutor against a member of Orion's Board of Directors for a suspected securities market offence dismissed

ORION CORPORATION STOCK EXCHANGE RELEASE 10 JUNE 2022 7:15 p.m. EEST

Charges pressed by prosecutor against a member of Orion’s Board of Directors for a suspected securities market offence dismissed

Charges pressed by prosecutor against a member of Orion’s Board of Directors for a suspected securities market offence dismissed

It has come to the attention of Orion Corporation the charges pressed by prosecutor against Ari Lehtoranta, a member of Orion’s Board of Directors, in a securities markets case concerning suspected disclosure offence have been dismissed.

According to Orion’s knowledge, the matter was related to Mr. Lehtoranta’s operations as the CEO of Nokian Tyres plc in 2015-2016. Orion Corporation disclosed the prosecutor’s decision to press charges in its stock exchange release of 29 October 2020. The suspected offence was not related to Orion. Orion will not comment the matter.

Orion Corporation

Timo Lappalainen President and CEO		Olli Huotari SVP, Corporate Functions

Contact person:

Terhi Ormio, VP, Communications

tel. +358 10 426 4646

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

http://www.orion.fi/en

http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are oncology and pain. Orion's net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.